Pharmaceuticals Global On demand · 24-48h

Global Motherwort Drug Market Strategic Research Report

Global Motherwort Drug Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Motherwort Drug Market
$2822025
6.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Granule, Paste/Extract, Tablet, Powder, Capsule, Oral Solution, Injection, Tincture/Drops

By Application: Irregular Menstruation, Menstrual Discomfort, Postpartum Recovery, Edema and Oliguria (Low Urine Output), Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Beijing TRT Group, Hainan Huluwa Pharmaceutical Group, HAPHARM GROUP, Chengdu First Pharmaceutical, Beijing Great Wall Pharmaceutical Co., Ltd., Zhejiang Wecome Pharmaceutical, Yingke Biopharma, Jiangxi Pinxin Pharmaceutical, Shenyang Yongda Pharmaceutical, Dade Holdings Group, Li Shizhen Pharmaceutical Group, Heilongjiang ZBD Pharmaceutical, Kangmei Baoning (Sichuan) Pharmaceutical, Anhui Huifeng Guoyao, Jiuhua Huayuan Pharmaceutical, Guangzhou Baiyunshan Pangao Shou Pharmaceutical, Anqing Huiyinbi Pharmaceutical, Shineway Pharmaceutical Group, Hengtuo Group Nanning Rensheng Pharmaceutical, Sichuan Deyuan Pharmaceutical Group, Shanghai Baolong Pharmaceutical, Herb Pharm, Gaia Herbs

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 159 pages
Market size 2025
$282
Million USD
Forecast CAGR
6.3%
2025-2032
Forecast 2032
$432.5
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Motherwort Drug market size is predicted to grow from US$ 282 million in 2025 to US$ 431 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.

In 2025, global production of motherwort drugs reached 131 million units, with an estimated average selling price of US$2.2 per unit. Motherwort drugs refer to gynecological products for regulating menstruation, postpartum recovery, or herbal health management, made primarily from motherwort through extraction, concentration, granulation, paste preparation, tableting, capsule encapsulation, or preparation as tinctures/herbal drops. These mainly correspond to traditional Chinese medicine preparations such as motherwort granules, motherwort paste, motherwort tablets, motherwort capsules, and motherwort oral liquid. Their main functions are "regulating menstruation and nourishing blood, resolving blood stasis and promoting new blood production," used for menstrual disorders, dysmenorrhea, scanty and dark menstrual flow caused by blood stasis and qi stagnation. The upstream of the industry chain includes the planting, harvesting, drying, processing of medicinal slices of motherwort, production of motherwort extract, sucrose/dextrin/honey/excipients, packaging materials, testing equipment, and GMP production systems; the midstream consists of traditional Chinese medicine companies and herbal preparation companies; and the downstream mainly includes hospital gynecology departments, primary healthcare institutions, pharmacies, chain pharmacies, e-commerce platforms, and cross-border traditional Chinese medicine retail. The gross profit margin is approximately 25%–40%.

Regionally, the Asia-Pacific market—led by China—is the core market and is maintaining rapid growth. In North America, the market is primarily driven by channels serving the Chinese community and herbal supplements, while in Europe, products appear mostly in forms such as tinctures, extracts, and capsules. Looking ahead, the development of motherwort products will trend toward sugar-free granules, low-sugar or portable stick packs, standardized extracts, branded OTC positioning, e-commerce expansion, segmentation for women's health, applications in postpartum recovery, compliance for overseas herbal supplements, and traceability of raw material quality.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Motherwort Drug market?

What factors are driving Motherwort Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Motherwort Drug market opportunities vary by end market size?

How does Motherwort Drug break out by Type, by Application?

This report presents a comprehensive overview of the global Motherwort Drug market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Granule
  • Paste/Extract
  • Tablet
  • Powder
  • Capsule
  • Oral Solution
  • Injection
  • Tincture/Drops

Segment by Regulatory Classification

  • Proprietary Chinese Medicine
  • OTC Herbal Medicine
  • Prescription Medicine
  • Dietary Supplement

Segment by Application

  • Online Sales
  • Offline Sales

Segment by Application

  • Irregular Menstruation
  • Menstrual Discomfort
  • Postpartum Recovery
  • Edema and Oliguria (Low Urine Output)
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Motherwort Drug market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Irregular Menstruation, Menstrual Discomfort, Postpartum Recovery evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Motherwort Drug Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$282
2025
Forecast
$432.5
2032
CAGR
6.3%
2025–2032
Régions
5
global
Key companies
Beijing TRT GroupHainan Huluwa Pharmaceutical GroupHAPHARM GROUPChengdu First PharmaceuticalBeijing Great Wall Pharmaceutical Co., Ltd.Zhejiang Wecome PharmaceuticalYingke BiopharmaJiangxi Pinxin Pharmaceutical
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
GranulePaste/ExtractTabletPowderCapsuleOral SolutionInjectionTincture/Drops
By Application
Irregular MenstruationMenstrual DiscomfortPostpartum RecoveryEdema and Oliguria (Low Urine Output)Others

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Granule
  • 3.1.3 Paste/Extract
  • 3.1.4 Tablet
  • 3.1.5 Powder
  • 3.1.6 Capsule
  • 3.1.7 Oral Solution
  • 3.1.8 Injection
  • 3.1.9 Tincture/Drops
  • 3.1.10 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Irregular Menstruation
  • 4.1.3 Menstrual Discomfort
  • 4.1.4 Postpartum Recovery
  • 4.1.5 Edema and Oliguria (Low Urine Output)
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Beijing TRT Group
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Hainan Huluwa Pharmaceutical Group
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 HAPHARM GROUP
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Chengdu First Pharmaceutical
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Beijing Great Wall Pharmaceutical Co., Ltd.
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Zhejiang Wecome Pharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Yingke Biopharma
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Jiangxi Pinxin Pharmaceutical
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Shenyang Yongda Pharmaceutical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Dade Holdings Group
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Li Shizhen Pharmaceutical Group
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Heilongjiang ZBD Pharmaceutical
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Kangmei Baoning (Sichuan) Pharmaceutical
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Anhui Huifeng Guoyao
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Jiuhua Huayuan Pharmaceutical
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Guangzhou Baiyunshan Pangao Shou Pharmaceutical
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Anqing Huiyinbi Pharmaceutical
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Shineway Pharmaceutical Group
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Hengtuo Group Nanning Rensheng Pharmaceutical
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Sichuan Deyuan Pharmaceutical Group
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Shanghai Baolong Pharmaceutical
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Herb Pharm
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Gaia Herbs
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Motherwort Drug market?
The global Motherwort Drug market is estimated at US$ 282 million in 2025 (base year) and is projected to reach US$ 431 million by 2032.
How fast is the Motherwort Drug market expected to grow?
The market is expected to grow at a CAGR of 6.3% from 2026 to 2032, expanding from US$ 282 million in 2025 to US$ 431 million in 2032, roughly 1.5 times its base-year value.
What does the Motherwort Drug market cover?
In 2025, global production of motherwort drugs reached 131 million units, with an estimated average selling price of US$2.2 per unit. Motherwort drugs refer to gynecological products for regulating menstruation, postpartum recovery, or herbal health management, made primarily from motherwort through extraction, concentration, granulation, paste preparation, tableting, capsule encapsulation, or preparation as tinctures/herbal drops.
What are the main segments of the Motherwort Drug market by type?
By type, the market is segmented into Granule, Paste/Extract, Tablet, Powder, Capsule, Oral Solution, Injection and Tincture/Drops.
Which applications drive demand in the Motherwort Drug market?
Key applications covered include Irregular Menstruation, Menstrual Discomfort, Postpartum Recovery, Edema and Oliguria (Low Urine Output) and Others.
Who are the key players in the Motherwort Drug market?
Key players profiled include Beijing TRT Group, Hainan Huluwa Pharmaceutical Group, HAPHARM GROUP, Chengdu First Pharmaceutical, Beijing Great Wall Pharmaceutical Co., Zhejiang Wecome Pharmaceutical, Yingke Biopharma and Jiangxi Pinxin Pharmaceutical, among 23 companies covered in total.
Which regions and countries are covered for Motherwort Drug?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Motherwort Drug market?
In North America, the market is primarily driven by channels serving the Chinese community and herbal supplements, while in Europe, products appear mostly in forms such as tinctures, extracts, and capsules.
Who should buy the Motherwort Drug market report?
The report is intended for manufacturers and solution providers, distributors and end users in Irregular Menstruation, Menstrual Discomfort and Postpartum Recovery, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Motherwort Drug market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.